ANL (Adlai Nortye) OCF Margin %: -366.62% (As of Dec. 2025)


What is Adlai Nortye OCF Margin %?

Adlai Nortye ANL -1.57% OCF Margin % is -366.62% as of Dec. 2025. The stock has 7 warning signs investors should review. Among 959 Biotechnology companies, Adlai Nortye ranks worse than 76.64% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Adlai Nortye's Cash Flow from Operations for the six months ended in Dec. 2025 was $-18.33 Mil. Adlai Nortye's Revenue for the six months ended in Dec. 2025 was $5.00 Mil. Therefore, Adlai Nortye's OCF Margin % for the quarter that ended in Dec. 2025 was -366.62%.

As of today, Adlai Nortye's current OCF Yield % is -5.19%.

The historical rank and industry rank for Adlai Nortye's OCF Margin % or its related term are showing as below:

ANL' s OCF Margin % Range Over the Past 10 Years
Min: -669.04   Med: -337.84   Max: -6.64
Current: -669.04

During the past 5 years, the highest OCF Margin % of Adlai Nortye was -6.64%. The lowest was -669.04%. And the median was -337.84%.

ANL's OCF Margin % is ranked worse than
76.64% of 959 companies
in the Biotechnology industry
Industry Median: -66.52 vs ANL: -669.04

Adlai Nortye OCF Margin % Related Terms

Adlai Nortye OCF Margin % Historical Data

* Premium members only.

The historical data trend for Adlai Nortye's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adlai Nortye OCF Margin % Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
-6.64 0.00 0.00 0.00 -669.04

Adlai Nortye Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 -366.62

ANL vs PHAT, AURA, RLMD: OCF Margin % Comparison

For the Biotechnology subindustry, Adlai Nortye's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adlai Nortye OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adlai Nortye's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Adlai Nortye's OCF Margin % falls into.


Adlai Nortye OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Adlai Nortye's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-33.452/5
=-669.04 %

Adlai Nortye's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-18.331/5
=-366.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -366.62% mean?
Adlai Nortye (ANL) has a OCF Margin % of -366.62% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Adlai Nortye and its competitors. According to the industry distribution chart, Adlai Nortye ranks #735 out of 959 companies in the Biotechnology industry, placing it in the top 76.6%.
Is Adlai Nortye's OCF Margin % too high?
Adlai Nortye's current OCF Margin % is -366.62%. Based on the distribution chart, Adlai Nortye ranks #735 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Adlai Nortye's OCF Margin % compare to PHAT and AURA?
According to the Biotechnology industry distribution chart, Adlai Nortye ranks #735 out of 959 companies for OCF Margin %. This places Adlai Nortye in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Adlai Nortye and its competitors. Adlai Nortye's current OCF Margin % is -366.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current OCF Margin % of -366.62%. The current OCF Margin % is -366.62%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Adlai Nortye (ANL), the current OCF Margin % is -366.62% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adlai Nortye Business Description

Other Exchanges N2U0:Germany
Address 685 US Highway 1, New Jersey Biotechnology Development Center, 2nd Floor, North Brunswick, NJ, USA, 08902
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.